First ALS affected person dosed in Section 1 trial checking out Quralis’ QRL-101
Quralis has dosed the primary affected person in a Section 1 medical trial checking out QRL-101 — its remedy candidate for lowering nerve cellular overactivation in amyotrophic lateral sclerosis (ALS) and thus